RXRihao Xu

Rihao Xu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rihao Xu has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Gemella morbillorum endocarditis of pulmonary valve:a case report

    by Dan Li, Zhicheng Zhu, Xiaomei Zheng, Weitie Wang, Rihao Xu, Kexiang Liu

    Pulmonary valve infective endocarditis is a rare finding for endocarditis. Infective endocarditis caused by Gemella morbillorum remains a scanty occurrence. This is a case reported of a 28-year-old Chinese male with endocarditis caused by pulmonary valve infection of Gemella morbillorum associated with congenital ventricular septal defect, atrial septal defect and double-chambered right ventricle. The patient presented with fever, shortness of breath, progressively worsening exertional fatigue, dyspnea and weight loss for 3 months. The diagnosis was made with transthoracic echocardiogram, blood cultures, and post-operative pathology. The patient developed congestive heart failure and was managed with aggressive antibiotic therapy followed by surgery. He underwent replacement of the pulmonary valve with an aortic bioprosthetic valve, repair of ventricular septal defect and atrial septal defect, reconstruction of the right ventricular outlflow tract, and excision of vegetations. His postoperative recovery was uneventful. No bacteria were isolated from the excised tissues. He was asymptomatic without recurrence at 3-month follow-up. The rare pathogen such as Gemella morbillorum can be the cause of infective endocarditis and timely surgical repair is necessary if the infection is refractory or there is progression of congestive heart failure under antibiotic cover.


  • Open Access

    Undifferentiated sarcoma originating from the mitral valve: a case report

    by Haibin Zhang, Weitie Wang, Dan Li, Zhicheng Zhu, Tiance Wang, Rihao Xu, Kexiang Liu

    Primary cardiac sarcomas are quite uncommon. Among them, sarcomas originating from the mitral valve are exceedingly rare. They are often misdiagnosed due to non-specific symptoms. The prognosis of cardiac sarcomas remains poor, and finding a more effective therapy poses a big challenge for the doctors. Currently, complete surgical resection of the tumor is still the most popular treatment in cases that without metastases. A 38-year-old female was transported to our department with persistent cough and chest pain. The operation of mitral valve replacement was scheduled after a provisional diagnosis of serious mitral stenosis. During the operation, we found that a large polypoid mass infiltrating mainly the mitral valve and part of the left atria. We removed the tumor as completely as possible and replaced the mitral valve. Histology confirmed the diagnosis of undifferentiated sarcoma after operation. The patient was asymptomatic with no recurrence at 3-month follow-up. Primary cardiac sarcomas is a rare and the prognosis is poor. The sarcomas is often found by chance during the operation. Surgical operation need to be carried out directly.


  • Open Access

    Cardiac lipoma in the interventricular septum: a case report

    by Dan Li, Weitie Wang, Zhicheng Zhu, Yuefeng Wang, Rihao Xu, Kexiang Liu


  • Open Access

    Combination use of platelets and recombinant activated factor VII for increased hemostasis during acute type a dissection operations

    by Wen Yan, Chengluan Xuan, Guojia Ma, Liang Zhang, Ning Dong, Zijian Wang, Rihao Xu

    Refractory blood loss is a common problem in surgeries for acute type A aortic dissections. Significant evidence has supported the benefit of using recombinant activated factor VII (rFVIIa) to control of intractable bleeding in patients after cardiac surgery. In this prospective clinical study, we present a novel method to achieve intraoperative hemostasis by using a combination of platelets and rFVIIa during operations for acute type A aortic dissections. Between May 2009 and August 2012, 71 patients with acute type A dissections who underwent emergency surgery were prospectively included and allocated to one of the following two intervention groups for hemostasis: 3 units platelets combined with 2.4 mg rFVIIa (n = 25), and conventional methods (n = 46). The patients who received the combination of platelets and rFVIIa required fewer transfusions of red blood cells (6.2 ± 3.1 units vs 9.8 ± 2.8 units; p < 0.05), fresh frozen plasma (736.9 ± 178.3 ml vs 1264.3 ± 245.2 ml, p < 0.05), platelet concentrates (3 units vs 5.0 ± 1.8 units, p < 0.001), and cryoprecipitate (2.8 ± 0.9 units vs 8.2 ± 2.3 units, p < 0.05). These patients also required less time for sternal closure (76.9 ± 17.2 min vs 102.3 ± 10.7 min, p < 0.05) compared with the conventional therapy patients. There was no statistically significant difference in the incidence of serious adverse events between these two groups. Using a combination of platelets and rFVIIa is an effective strategy for achieving hemostasis during acute type A dissection surgery. This hemostatic strategy does not appear to be associated with an increase in postoperative adverse events.